PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT06660992 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT669
EST. COMPLETION2026-11-28

Conditions

Non-cystic Fibrosis Bronchiectasis

Interventions

HSK31858, tabletPlacebo

Study details

SPONSORHaisco Pharmaceutical Group Co., Ltd.
START DATE2024-09-30

Related company profiles

Haisco Pharmaceutical Group

002653.SZ

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT06660992
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record